| 3.24 -0.2 (-5.81%) | 07-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.24  |
1-year : | 4.56 |
| Resists | First : | 3.63 |
Second : | 3.91 |
| Pivot price | 3.61 |
|||
| Supports | First : | 3.18 |
Second : | 2.64 |
| MAs | MA(5) : | 3.57 |
MA(20) : | 3.6 |
| MA(100) : | 3.84 |
MA(250) : | 3.95 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 21 |
D(3) : | 40.1 |
| RSI | RSI(14): 36.6 |
|||
| 52-week | High : | 5.55 | Low : | 2.88 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VYGR ] has closed below the lower bollinger band by 17.6%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ VYGR ] is to continue within current trading range. Bollinger Bands are 34.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.41 - 3.43 | 3.43 - 3.45 |
| Low: | 3.12 - 3.15 | 3.15 - 3.18 |
| Close: | 3.2 - 3.24 | 3.24 - 3.27 |
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Mon, 13 Jul 2026
Voyager reports VY1706 Alzheimer’s therapy data - grafa.com
Mon, 13 Jul 2026
Voyager presents six-month data for Alzheimer’s gene therapy - Investing.com UK
Mon, 13 Jul 2026
Voyager Therapeutics (VYGR) Reports Promising VY1706 Data for Al - GuruFocus
Mon, 13 Jul 2026
[8-K] Voyager Therapeutics, Inc. Reports Material Event - Stock Titan
Mon, 13 Jul 2026
Single-dose Alzheimer’s gene therapy from Voyager lowers brain tau in primates - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 4.422e+007 (%) |
| Held by Institutions | 15.1 (%) |
| Shares Short | 3,740 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.1994e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 167.3 % |
| Return on Equity (ttm) | -27.1 % |
| Qtrly Rev. Growth | 3.649e+007 % |
| Gross Profit (p.s.) | -47.17 |
| Sales Per Share | -41.15 |
| EBITDA (p.s.) | -6.99685e+007 |
| Qtrly Earnings Growth | -2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -128 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.08 |
| Price to Cash Flow | 1.42 |
| Dividend | 0 |
| Forward Dividend | 3.57e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|